Table 2.
Examples of clinical studies exploring p53-oriented therapies in solid tumors.
| Study ID | Phase | Drug | Mechanism of Action |
|---|---|---|---|
| NCT02429726 | II | Recombinant adenoviral human p53 | Replacement of defective p53. |
| NCT00004038 | I | ||
| NCT00004041 | I | ||
| NCT00003588 | I | ||
| NCT00003167 | I | ||
| NCT02429037 | II | ||
| NCT00004225 | I | ||
| NCT00894153 | IV | ||
| NCT00902122 | IV | ||
| NCT00902083 | IV | ||
| NCT02435186 | II | ||
| NCT01574729 | II | ||
| NCT03544723 | II | ||
| NCT02842125 | I/II | ||
| NCT00776295 | II | ||
| NCT02340117 | II | SGT-53 (cationic liposome encapsulating p53) | |
| NCT02340156 | II | ||
| NCT01639885 | II | Vaccine from tp53-derived peptides | Immune-mediated elimination of p53 mutated neoplastic clones. |
| NCT00001827 | II | ||
| NCT00844506 | II | ||
| NCT02577588 | I | Adoptive transfer of ex vivo reactivated p53 specific T cells | |
| NCT03113487 | II | Modified vaccinia virus Ankara vaccine expressing p53 | |
| NCT02432963 | I | ||
| NCT01191684 | I | ||
| NCT02275039 | I | ||
| NCT00019916 | I/II | Autologous peripheral blood-derived antigen-presenting cells pulsed in vitro with p53-derived | |
| NCT00978913 | I | ||
| NCT00019929 | II | ||
| NCT00617409 | II | ||
| NCT00082641 | I/II | Autologous dendritic cells pulsed with adenovirus p53 | |
| NCT01042535 | I/II | ||
| NCT00393029 | II | TP53/T-cell receptor transduced peripheral blood lymphocytes | |
| NCT00496860 | I/II | ALT-801 | Induction of immune response against p53+ cells. The drug is a bifunctional fusion protein comprising interleukin-2 linked to a soluble, single-chain T-cell receptor domain that recognizes a peptide epitope (aa264–272) of the human p53 antigen displayed on cancer cells in the context of HLA-A*0201 (p53+/HLA-A*0201). |
| NCT01029873 | I/II | ||
| NCT01760525 | I | CGM097 | MDM2 inhibition. |
| NCT05180695 | I/II | HDM201 | |
| NCT02143635 | I/II | ||
| NCT03781986 | I/II | APG-115 | |
| NCT03611868 | I/II | ||
| NCT03975387 | I/II | ASTX295 | |
| NCT03217266 | I | Navtemadlin | |
| NCT02264613 | I/II | ALRN-6924 | |
| NCT04585750 | I/II | PC14586 | Small molecule “reactivating” p53. It binds to the crevice of mutant p.Y220C p53, restoring the normal structure and tumor suppressing function. |
| NCT01975116 | I | Azurin-derived cell-penetrating peptide p28 | After preferentially penetrating cancer cells, azurin induces a post-translational increase in p53 by inhibiting its ubiquitination. |
| NCT02098343 | I/II | APR-246 | It binds to cysteine residues in mutant p53, thereby producing thermo dynamic stabilization of the protein and shifting equilibrium toward a functional conformation. |
| NCT03268382 | I |
Only therapeutic studies were selected. Diagnostic, prognostic or early detection studies were not included. Clinical trials whose status was “unknown” or “withdrawn” or “suspended” were not included into this table (reporting only active or completed trials).